Teledyne Technologies (TDY) At $181.24 Forms Top; Ardsley Advisory Partners Has Cut Alexion Pharmaceuticals (ALXN) Position

Ardsley Advisory Partners decreased Alexion Pharmaceuticals Inc (ALXN) stake by 2.83% reported in 2017Q3 SEC filing. Ardsley Advisory Partners sold 5,000 shares as Alexion Pharmaceuticals Inc (ALXN)’s stock declined 11.63%. The Ardsley Advisory Partners holds 171,500 shares with $24.06M value, down from 176,500 last quarter. Alexion Pharmaceuticals Inc now has $26.54B valuation. The stock increased 0.46% or $0.54 during the last trading session, reaching $118.78. About 991,743 shares traded. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has declined 18.12% since December 23, 2016 and is downtrending. It has underperformed by 34.82% the S&P500.

Teledyne Technologies Incorporated (TDY) formed multiple top with $188.49 target or 4.00% above today’s $181.24 share price. Teledyne Technologies Incorporated (TDY) has $6.42B valuation. The stock decreased 0.04% or $0.07 during the last trading session, reaching $181.24. About 142,812 shares traded. Teledyne Technologies Incorporated (NYSE:TDY) has risen 37.51% since December 23, 2016 and is uptrending. It has outperformed by 20.81% the S&P500.

Analysts await Teledyne Technologies Incorporated (NYSE:TDY) to report earnings on February, 1. They expect $1.74 EPS, up 5.45% or $0.09 from last year’s $1.65 per share. TDY’s profit will be $61.66 million for 26.04 P/E if the $1.74 EPS becomes a reality. After $1.96 actual EPS reported by Teledyne Technologies Incorporated for the previous quarter, Wall Street now forecasts -11.22% negative EPS growth.

Since August 7, 2017, it had 0 buys, and 4 sales for $2.96 million activity. Another trade for 4,000 shares valued at $584,800 was made by Cibik Melanie Susan on Wednesday, August 9. Another trade for 6,000 shares valued at $882,441 was sold by VanWees Jason. 4,000 Teledyne Technologies Incorporated (NYSE:TDY) shares with value of $593,200 were sold by AUSTIN ROXANNE S. LORNE SIMON M sold $900,559 worth of stock.

Investors sentiment decreased to 1.28 in Q3 2017. Its down 0.03, from 1.31 in 2017Q2. It turned negative, as 27 investors sold Teledyne Technologies Incorporated shares while 68 reduced holdings. 39 funds opened positions while 83 raised stakes. 29.58 million shares or 1.93% more from 29.02 million shares in 2017Q2 were reported. 2,975 are owned by Oakbrook Investments Lc. Td Asset Management Inc reported 22,560 shares. 25,795 are owned by Texas Permanent School Fund. Zacks Invest Mgmt holds 9,099 shares or 0.03% of its portfolio. 253 were accumulated by Point72 Asia (Hong Kong). Fortaleza Asset Management stated it has 1,736 shares. Congress Asset Management Ma accumulated 10,230 shares. Sg Americas Securities Ltd holds 0% of its portfolio in Teledyne Technologies Incorporated (NYSE:TDY) for 676 shares. Weik Svcs Inc holds 0.43% of its portfolio in Teledyne Technologies Incorporated (NYSE:TDY) for 5,650 shares. Paloma Prtn Mgmt invested in 1,544 shares or 0% of the stock. Neuberger Berman Ltd Limited Liability Company holds 229,053 shares. 101,584 were reported by Loomis Sayles Limited Partnership. Moreover, Glenmede Na has 0% invested in Teledyne Technologies Incorporated (NYSE:TDY) for 111 shares. 2,819 were accumulated by Ironwood Investment Management. Thompson Davis And Company has 259 shares.

Among 3 analysts covering Teledyne Tech (NYSE:TDY), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. Teledyne Tech had 11 analyst reports since October 6, 2015 according to SRatingsIntel. As per Thursday, August 3, the company rating was maintained by Jefferies. Jefferies maintained Teledyne Technologies Incorporated (NYSE:TDY) rating on Tuesday, June 6. Jefferies has “Hold” rating and $14000 target. The stock of Teledyne Technologies Incorporated (NYSE:TDY) earned “Hold” rating by Jefferies on Friday, October 6. Jefferies maintained Teledyne Technologies Incorporated (NYSE:TDY) on Friday, July 14 with “Hold” rating. The stock of Teledyne Technologies Incorporated (NYSE:TDY) has “Hold” rating given on Friday, July 7 by Jefferies. The firm has “Hold” rating given on Tuesday, September 5 by Jefferies. As per Wednesday, July 5, the company rating was upgraded by Needham. The stock has “Buy” rating by Needham on Friday, November 3. The stock of Teledyne Technologies Incorporated (NYSE:TDY) has “Neutral” rating given on Wednesday, July 6 by CL King. The stock has “Hold” rating by Jefferies on Friday, November 3.

Since July 31, 2017, it had 0 insider buys, and 5 insider sales for $2.43 million activity. O’Neill Julie sold $1.56M worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on Monday, August 28. 835 shares were sold by Veneman Ann M, worth $121,751. Wagner Heidi L had sold 120 shares worth $16,800 on Monday, October 2.

Ardsley Advisory Partners increased Zimmer Biomet Hldgs Inc (ZMH) stake by 105,500 shares to 110,000 valued at $12.88M in 2017Q3. It also upped Cree Inc (NASDAQ:CREE) stake by 32,500 shares and now owns 107,500 shares. Nrg Yield Inc was raised too.

Analysts await Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) to report earnings on February, 15. They expect $1.08 EPS, down 1.82% or $0.02 from last year’s $1.1 per share. ALXN’s profit will be $241.29M for 27.50 P/E if the $1.08 EPS becomes a reality. After $1.28 actual EPS reported by Alexion Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -15.63% negative EPS growth.

Among 28 analysts covering Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), 23 have Buy rating, 0 Sell and 5 Hold. Therefore 82% are positive. Alexion Pharmaceuticals Inc. has $257 highest and $82 lowest target. $169.33’s average target is 42.56% above currents $118.78 stock price. Alexion Pharmaceuticals Inc. had 88 analyst reports since July 27, 2015 according to SRatingsIntel. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) earned “Overweight” rating by JP Morgan on Monday, July 27. The stock has “Hold” rating by Robert W. Baird on Tuesday, October 24. Robert W. Baird upgraded the stock to “Outperform” rating in Monday, December 18 report. The firm has “Buy” rating by Nomura given on Monday, July 17. As per Friday, July 31, the company rating was maintained by Brean Capital. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) earned “Neutral” rating by BTIG Research on Thursday, January 7. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) earned “Outperform” rating by Credit Suisse on Monday, July 11. Stifel Nicolaus maintained the shares of ALXN in report on Friday, December 11 with “Buy” rating. The company was initiated on Thursday, February 25 by Citigroup. Morgan Stanley upgraded Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on Thursday, May 25 to “Overweight” rating.